semaglutide fda changes just got FDA-approved for kidney disease. This everything., January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in What the FDA's update on

Boots notes

Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine

For a broader view of that research arc, our retatrutide clinical trials update covers the main findings and why the Phase 3 story matters

Seek a cash-pay alternative to traditional insurance pathways: Consumers who do not have insurance coverage for GLP-1 medications, or who face high out-of-pocket costs through traditional channels, may find the platform's published pricing competitive within the cash-pay telehealth category

The tirzepatide dosing landscape shifted dramatically as a result of these regulatory changes